ClinicalTrials.gg
CompletedNCT05684796Updated Aug 18, 2026Results posted

Comparison of Two Pulmonary Embolism Treatments

An interventional study of Anticoagulation and mechanical aspiration thrombectomy in Pulmonary Embolism Acute, sponsored by Penumbra Inc.. Completed at 22 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Penumbra Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Enrollment
108th of 166
100 · median 142
Started
2023
with 14 others
No phase
82 of 236
17 open now
Registered
195th of 236
by date

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 108th largest by enrollment of the 166 interventional ones that give a count, is one of 15 that started in 2023, is one of 82 with no phase, and was the 195th registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the safety and efficacy of treatment with anticoagulation alone versus anticoagulation and mechanical aspiration thrombectomy with the Indigo Aspiration System for the treatment of intermediate-high risk acute pulmonary embolism (PE).

03

Conditions studied

  • Pulmonary Embolism Acute

Browse trials for

Keywords

  • intermediate-high risk
  • acute
  • PE
  • clot
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 years old
  2. Clinical signs and symptoms consistent with acute PE with duration of 14 days or less
  3. Objectively confirmed acute PE, based on computed tomographic pulmonary angiography (CTPA) imaging showing a filling defect in at least one main or proximal lobar pulmonary artery
  4. Classification of intermediate high-risk PE as demonstrated by right ventricular dysfunction with RV/LV ratio ≥1.0 on CTPA and elevated cardiac biomarkers, including cardiac troponin, BNP, and/or NT-pro BNP above the
  5. Jugular or femoral access deemed suitable to accommodate pulmonary artery intervention with the Indigo Aspiration System
  6. is obtained from either the patient or legally authorized representative (LAR)

Exclusion criteria

Exclusion Criteria:

  1. Administration of thrombolytic agents or glycoprotein IIb/IIIa receptor antagonist within 30 days prior to baseline imaging
  2. Hemodynamic instability with any of the following present:

    1. Cardiac arrest
    2. Obstructive shock or persistent hypotension defined as systolic blood pressure (BP) \<90 mmHg or an acute drop in systolic BP ≥40 mmHg for >15 min, or requiring vasopressor or inotropic support to achieve a systolic BP ≥90 mmHg
  3. Patients on ECMO
  4. National Early Warning Score (NEWS) 2 ≥9
  5. History, imaging or hemodynamic findings consistent with chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis
  6. Imaging evidence or other evidence that suggests, in the opinion of the Investigator, that catheter-based intervention is not appropriate for the patient
  7. Allergy, , or heparin induced thrombocytopenia (HIT)
  8. or sensitivity to iodinated intravascular contrast that cannot be adequately premedicated
  9. \<45 mL/min
  10. Severe active infection (e.g. sepsis) requiring treatment at time of enrollment
  11. Active bleeding or disorders contraindicating anticoagulant therapy
  12. \<10 g/dL
  13. \<100,000/μL
  14. >3
  15. Cardiovascular or pulmonary surgery within last 7 days
  16. Primary brain or brain cancer
  17. \<90 days
  18. Pregnancy
  19. Intracardiac thrombus (right atrium, right ventricle clot in transit) or thrombus in the inferior vena cava identified on baseline imaging
  20. Current participation in another drug or device trial that may confound the results of this trial. Studies requiring extended follow-up for products that were investigational but have since become commercially available are not considered investigational studies.
  21. Other medical, social, or psychological conditions that, in the opinion of the Investigator, precludes the patient from appropriate consent, could limit the patient's ability to participate in the trial, including compliance with follow-up requirements, or that could impact the scientific integrity of the trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Active comparator
    Anticoagulation (AC)

    Subjects will have their pulmonary embolism treated with anticoagulants alone. There will be no procedure for this group.

    Drug: Anticoagulation

  • Active comparator
    Indigo

    Subjects will have their pulmonary embolism treated with anticoagulants and mechanical aspiration thrombectomy with the Indigo® Aspiration System.

    Device: mechanical aspiration thrombectomy

Interventions

  • DrugAnticoagulation

    Anticoagulation with unfractionated heparin (UFH) or low molecular weight heparin (LMWH)

  • Devicemechanical aspiration thrombectomy

    Mechanical aspiration thrombectomy with the Indigo Aspiration System.

    Also known as: Indigo Aspiration System

06

What researchers measure

Primary outcomes

  1. Change in RV/LV Ratio

    Change in RV/LV ratio at 48 hours on original therapy as assessed by computed tomography pulmonary angiography (CTPA). Negative change values represent a reduction in the ratio of right ventricular to left ventricular diameter, consistent with improvement in right ventricular dilation.

    Time frame: 48 hours post-randomization

Secondary outcomes

  1. Major Adverse Events

    Major adverse events (MAEs) within 7 days: a composite of clinical deterioration requiring escalation of care, PE-related mortality, symptomatic recurrent PE, or major bleeding

    Time frame: within 7 days post-randomization

  2. Functional Outcome Assessment With the 6-minute Walk Test

    Functional outcome as assessed by the 6-minute walk test (6MWT) through 90 days. The 6-minute walk test measures distance walked in meters, with longer distances being better.

    Time frame: Through 90 days post-randomization

  3. Functional Outcome Assessment With the New York Heart Association Classification

    Functional outcome as assessed by the New York Heart Association classification (NYHA) through 90 days. The New York Heart Association classification ranges from Class I (no limitations) -IV (severe limitation), with higher classifications being worse.

    Time frame: Through 90 days post-randomization

  4. Functional Outcome Assessment With the Post Venous Thromboembolism Functional Status Scale

    Functional outcome as assessed by the Post Venous Thromboembolism Functional Status (PVFS) scale through 90 days. The Post Venous Thromboembolism Functional Status scale ranges from 0-5, with higher scores being worse.

    Time frame: Through 90 days post-randomization

  5. Functional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale

    Functional outcome as assessed by the modified Medical Research Council Dyspnea Scale (mMRC) through 90 days. The modified Medical Research Council Dyspnea Scale ranges from 0-4, with higher scores being worse.

    Time frame: Through 90 days post-randomization

  6. Functional Outcome Assessment With the Borg Scale

    Functional outcome as assessed by the Borg Scale through 90 days. The Borg Scale ranges from 0-10, with higher scores being worse.

    Time frame: Through 90 days post-randomization

  7. Quality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire

    Quality of Life (QoL), as assessed by the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) through 90 days. The Pulmonary Embolism Quality of Life Questionnaire measures the percent of life affected by PE across 6 dimensions (including: Frequency of complaints, Limitations in activities of daily living (ADL), Work-related problems, Social limitations, Intensity of complaints, Emotional complaints), with higher scores being worse.

    Time frame: Through 90 days post-randomization

  8. Quality of Life Assessment With the EQ-5D-5L Questionnaire

    Quality of Life (QoL), as assessed by the EQ-5D-5L Questionnaire through 90 days. The EQ-5D-5L index is a preference-weighted measure of health status derived from five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Index values represent overall health status, with higher scores indicating better health status. The Visual Analogue Scale (VAS) scale is part of the questionnaire and ranges from 0-100, with higher scores being better.

    Time frame: Through 90 days post-randomization

  9. All-cause Mortality

    All-cause mortality within 90 days

    Time frame: within 90 days post-randomization

  10. PE-related Mortality

    PE-related mortality within 90 days

    Time frame: within 90 days post-randomization

  11. Symptomatic PE Recurrence

    Symptomatic PE recurrence within 90 days

    Time frame: within 90 days post-randomization

07

Results

Posted Aug 18, 2026

Participant flow

Participant flow — Overall Study
MilestoneAnticoagulation (AC)Indigo
Started5347
Completed4743
Not completed64

Outcome measures

PrimaryChange in RV/LV Ratio

Change in RV/LV ratio at 48 hours on original therapy as assessed by computed tomography pulmonary angiography (CTPA). Negative change values represent a reduction in the ratio of right ventricular to left ventricular diameter, consistent with improvement in right ventricular dilation.

Time frame:
48 hours post-randomization
Reported as:
Mean · Change in RV/LV Ratio
Change in RV/LV Ratio
Change in RV/LV RatioAnticoagulation (AC)Indigo
Change in RV/LV Ratio-0.24 ± 0.40-0.52 ± 0.37
SecondaryMajor Adverse Events

Major adverse events (MAEs) within 7 days: a composite of clinical deterioration requiring escalation of care, PE-related mortality, symptomatic recurrent PE, or major bleeding

Time frame:
within 7 days post-randomization
Reported as:
Count of participants · Participants
Major Adverse Events
ParticipantsAnticoagulation (AC)Indigo
Major Adverse Events42
SecondaryFunctional Outcome Assessment With the 6-minute Walk Test

Functional outcome as assessed by the 6-minute walk test (6MWT) through 90 days. The 6-minute walk test measures distance walked in meters, with longer distances being better.

Time frame:
Through 90 days post-randomization
Reported as:
Mean · distance walked in meters
Functional Outcome Assessment With the 6-minute Walk Test
distance walked in metersAnticoagulation (AC)Indigo
Functional Outcome Assessment With the 6-minute Walk Test368.0 ± 127.78478.7 ± 159.47
SecondaryFunctional Outcome Assessment With the New York Heart Association Classification

Functional outcome as assessed by the New York Heart Association classification (NYHA) through 90 days. The New York Heart Association classification ranges from Class I (no limitations) -IV (severe limitation), with higher classifications being worse.

Time frame:
Through 90 days post-randomization
Reported as:
Count of participants · Participants
Functional Outcome Assessment With the New York Heart Association Classification
ParticipantsAnticoagulation (AC)Indigo
Class IV10
Class III21
Class II80
Class I3437
SecondaryFunctional Outcome Assessment With the Post Venous Thromboembolism Functional Status Scale

Functional outcome as assessed by the Post Venous Thromboembolism Functional Status (PVFS) scale through 90 days. The Post Venous Thromboembolism Functional Status scale ranges from 0-5, with higher scores being worse.

Time frame:
Through 90 days post-randomization
Reported as:
Count of participants · Participants
Functional Outcome Assessment With the Post Venous Thromboembolism Functional Status Scale
ParticipantsAnticoagulation (AC)Indigo
Severe functional limitations31
Moderate32
Slight78
Negligible85
No functional limitations2323
SecondaryFunctional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale

Functional outcome as assessed by the modified Medical Research Council Dyspnea Scale (mMRC) through 90 days. The modified Medical Research Council Dyspnea Scale ranges from 0-4, with higher scores being worse.

Time frame:
Through 90 days post-randomization
Reported as:
Mean · score on a scale
Functional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale
score on a scaleAnticoagulation (AC)Indigo
Functional Outcome Assessment With the Modified Medical Research Council Dyspnea Scale0.6 ± 0.950.4 ± 0.94
SecondaryFunctional Outcome Assessment With the Borg Scale

Functional outcome as assessed by the Borg Scale through 90 days. The Borg Scale ranges from 0-10, with higher scores being worse.

Time frame:
Through 90 days post-randomization
Reported as:
Median · score on a scale
Functional Outcome Assessment With the Borg Scale
score on a scaleAnticoagulation (AC)Indigo
Functional Outcome Assessment With the Borg Scale0 (0.0 to 0.3)0 (0.0 to 0.5)
SecondaryQuality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire

Quality of Life (QoL), as assessed by the Pulmonary Embolism Quality of Life Questionnaire (PEmb-QoL) through 90 days. The Pulmonary Embolism Quality of Life Questionnaire measures the percent of life affected by PE across 6 dimensions (including: Frequency of complaints, Limitations in activities of daily living (ADL), Work-related problems, Social limitations, Intensity of complaints, Emotional complaints), with higher scores being worse.

Time frame:
Through 90 days post-randomization
Reported as:
Mean · percent of life affected by PE
Quality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire
percent of life affected by PEAnticoagulation (AC)Indigo
Quality of Life Assessment With the Pulmonary Embolism Quality of Life Questionnaire21.7 ± 22.015.8 ± 20.0
SecondaryQuality of Life Assessment With the EQ-5D-5L Questionnaire

Quality of Life (QoL), as assessed by the EQ-5D-5L Questionnaire through 90 days. The EQ-5D-5L index is a preference-weighted measure of health status derived from five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Index values represent overall health status, with higher scores indicating better health status. The Visual Analogue Scale (VAS) scale is part of the questionnaire and ranges from 0-100, with higher scores being better.

Time frame:
Through 90 days post-randomization
Reported as:
Mean · score on a scale
Quality of Life Assessment With the EQ-5D-5L Questionnaire
score on a scaleAnticoagulation (AC)Indigo
Index0.811 ± 0.2210.811 ± 0.236
Visual Analog Scale77.9 ± 18.280.2 ± 14.9
SecondaryAll-cause Mortality

All-cause mortality within 90 days

Time frame:
within 90 days post-randomization
Reported as:
Count of participants · Participants
All-cause Mortality
ParticipantsAnticoagulation (AC)Indigo
All-cause Mortality14
SecondaryPE-related Mortality

PE-related mortality within 90 days

Time frame:
within 90 days post-randomization
Reported as:
Count of participants · Participants
PE-related Mortality
ParticipantsAnticoagulation (AC)Indigo
PE-related Mortality02
SecondarySymptomatic PE Recurrence

Symptomatic PE recurrence within 90 days

Time frame:
within 90 days post-randomization
Reported as:
Count of participants · Participants
Symptomatic PE Recurrence
ParticipantsAnticoagulation (AC)Indigo
Symptomatic PE Recurrence11

Adverse events

Collected over 90 days post-randomization. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Anticoagulation (AC)1/53 (1.9%)14/53 (26.4%)5/53 (9.4%)
Indigo4/47 (8.5%)11/47 (23.4%)8/47 (17%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventAnticoagulation (AC)Indigo
HemoptysisRespiratory, thoracic and mediastinal disorders0/531/47
Cardiac arrestCardiac disorders0/531/47
Left radial artery bleedInjury, poisoning and procedural complications0/531/47
New acute bilateral LE DVT and edemaVascular disorders0/531/47
Adenocarcinoma of the gastroesophageal junctionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/531/47
Anaphylactic ShockImmune system disorders0/531/47
Trauma (due to multiple gunshot wounds head, face, groin, R hip, L buttock)Injury, poisoning and procedural complications0/531/47
Severe TachycardiaCardiac disorders0/531/47
Failure to thriveMetabolism and nutrition disorders0/531/47
Recurrent Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/531/47
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAnticoagulation (AC)Indigo
HemoptysisRespiratory, thoracic and mediastinal disorders0/531/47
Severe Allergic ReactionImmune system disorders0/531/47
Perivascular LymphocyticSkin and subcutaneous tissue disorders0/531/47
Chest pain and SOBGeneral disorders0/531/47
Chest PainGeneral disorders0/531/47
PneumoniaInfections and infestations0/531/47
Duodenal UlcersGastrointestinal disorders0/531/47
DyspneaRespiratory, thoracic and mediastinal disorders0/531/47
AKIRenal and urinary disorders1/530/47
Worsening Urinary Tract InfectionInfections and infestations1/530/47

Baseline characteristics

Age, Continuous
Age, Continuous(years)Anticoagulation (AC)IndigoTotal
Mean61.2 ± 14.1959.5 ± 13.2260.4 ± 13.70
Sex: Female, Male
Sex: Female, Male(Participants)Anticoagulation (AC)IndigoTotal
Female281846
Male252954
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Anticoagulation (AC)IndigoTotal
Hispanic or Latino033
Not Hispanic or Latino493786
Unknown112
Not Reported033
Not collected due to local privacy regulations336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Anticoagulation (AC)IndigoTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American131831
White352257
More than one race000
Unknown or Not Reported145
Not collected due to local privacy regulations336
Other101
08

Study locations

22 sites
  • The University of Arizona - Banner
    Tucson, Arizona 85719, United States
  • UCLA Medical Center
    Los Angeles, California 90024, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Radiology and Imaging Specialists/Lakeland Regional
    Lakeland, Florida 33801, United States
  • Joseph Maxwell Cleland Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Wellstar Kennestone
    Marietta, Georgia 30060, United States
  • Northwestern Memorial
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • St. Elizabeth Edgewood Hospital
    Edgewood, Kentucky 41017, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • McLaren Bay Heart & Vascular
    Bay City, Michigan 48708, United States
  • Corewell Health William Beaumont University Hospital
    Royal Oak, Michigan 48073, United States
  • Cooper Health System
    Camden, New Jersey 08103, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Ascension Seton Medical Center Austin
    Austin, Texas 78705, United States
  • Baylor University Medical Center
    Dallas, Texas 75226, United States
  • Kingwood Medical Center
    Kingwood, Texas 77339, United States
  • Metropolitan Methodist Hospital
    San Antonio, Texas 78212, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Foothills Medical Centre
    Calgary, Alberta T2N 2T9, Canada
  • Auckland City Hospital
    Auckland, New Zealand
  • Krakowski Szpital Specjalistyczny św. Jana Pawła II
    Krakow, Poland
09

References and documents

Publications

  • Lookstein RA, Konstantinides SV, Weinberg I, Dohad SY, Rosol Z, Kopec G, Moriarty JM, Parikh SA, Holden A, Channick RN, McDonald B, Nagarsheth KH, Yamada K, Rosovsky RP; STORM-PE Trial Investigators. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial. Circulation. 2026 Jan 6;153(1):21-34. doi: 10.1161/CIRCULATIONAHA.125.077232. Epub 2025 Nov 3. PubMed 41183181 ↗
  • Rosovsky RP, Konstantinides SV, Moriarty JM, Dohad SY, Weinberg I, Parikh SA, Channick R, Lookstein RA. A prospective, multicenter, randomized controlled trial evaluating anticoagulation alone vs anticoagulation plus computer assisted vacuum thrombectomy for the treatment of intermediate-high-risk acute pulmonary embolism: Rationale and design of the STORM-PE study. Am Heart J. 2025 Oct;288:1-14. doi: 10.1016/j.ahj.2025.03.018. Epub 2025 Mar 31. PubMed 40174693 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jun 2025, 18 months.

Results were first posted in Aug 2026, 1 year 2 months after primary completion.

Of 150 interventional studies with no phase under Pulmonary Embolism, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 18 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2022
First posted
Jan 13, 2023
StartActual
Nov 27, 2023
Primary completionActual
Jun 12, 2025
CompletionActual
Sep 9, 2025
Results first posted
Aug 18, 2026
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05684796
Lead sponsor
Penumbra Inc.
Responsible party
Sponsor
First posted
Jan 13, 2023
Start date
Nov 27, 2023
Primary completion
Jun 12, 2025
Completion
Sep 9, 2025
Results posted
Aug 18, 2026
Last update
Aug 18, 2026

Study contacts

Rachel Rosovsky, MD
principal investigator · Massachusetts General Hospital
Robert Lookstein, MD
principal investigator · MOUNT SINAI HOSPITAL

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion